We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Swissmedic Narrows Approval Pathway For Heparin-Based Biosimilars
Swissmedic Narrows Approval Pathway For Heparin-Based Biosimilars
Unlike in the EU, Swiss regulators will not accept marketing authorization applications for biosimilars of low-molecular-weight heparin products already approved in Switzerland.